Latest Eisai News & Updates

See the latest news and media coverage for Eisai. We track all announcements, press releases, and industry mentions in real time, all in one place.

Eisai

Human health care company

eisai.com

Headquarters: Bunkyo-Ku, Japan
Company type: Public company
Number of employees: 1,000–5,000

Last updated Today

Latest news about Eisai

In short: Eisai announced a $7 billion three-year investment plan and aims for $7 billion in revenue by 2028, driven by the expansion of its Alzheimer's drug.

Company announcements

April 3 Eisai

Eisai opens new Global Capability Centre

The IT hub in Visakhapatnam, India, standardizes global IT operations and drives digital transformation. An opening ceremony celebrated its launch.

February 20 Eisai

Eisai receives human capital awards for third year

Eisai earns 'Thought Leaders of Human Capital 2025' and 'Human Capital Management Excellence 2025 Gold Award' for excellent management and disclosure.

January 26 Eisai

Eisai announces FDA acceptance of LEQEMBI IQLIK sBLA

The application for subcutaneous starting dose in early Alzheimer’s is under priority review with action date May 24, 2026.

January 21 Eisai

Eisai ranks 36th in Global 100 sustainability list

It marks Eisai's tenth inclusion and highest rank among global pharmaceutical companies. Evaluation based on UN SDGs, sustainable revenue, and investment.

Media coverage

June 16 mynavi news

Eisai announces 1 trillion yen investment, aiming to become a 'sharp drug discovery company' with three main drugs

As its main anticancer drug faces patent expiration, 'We will continue strategic efforts to evolve as a 'sharp drug discovery company',' emphasizes Keisuke Naito, Executive Officer, COO and Chief Growth Officer of Eisai. The company announced a three-year plan...

June 15 Nikkei

Eisai invests 10 billion yen in the UK

We will send newsletters and campaign information for the Nikkei electronic edition to the email address you registered (you can unsubscribe after registration). We will use your email address only for the purpose of sending these emails. You will not be automatically registered for other services such as Nikkei ID. Thank you for registering. We have sent an email to the email address you provided. Click the link in the email to read the full article...

June 15 Fierce Pharma

Eisai snares government manufacturing grant as it brings Leqembi packaging to UK with $65M expansion

As the United Kingdom juggles industry concerns about the region's waning appeal and competitiveness, Eisai is getting a lift from a production-tinged fund that the...

June 4 Nikkei Biotech Online

Eisai formulates three-year plan, focusing on expanding sales of 'Leqembi' and more...

Eisai held a management strategy briefing on May 25, 2026, and announced its three-year plan for fiscal years 2026–2028. Along with the goal of achieving ¥1 trillion in sales revenue in fiscal 2028 through expansion of sales of the Alzheimer's disease (AD) treatment drug 'Leqembi' (lecanemab) and other measures, the company outlined R&D strategies and new financial policies to solidify the foundation for sustainable growth.

Never miss news about Eisai

Track Eisai and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Eisai competitors & trending companies

Browse news for competitors to Eisai and other trending companies.